• Je něco špatně v tomto záznamu ?

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes

DG. Sweet, M. Turner, Z. Straňák, R. Plavka, P. Clarke, B. Stenson, D. Singer, R. Goelz, L. Fabbri, G. Varoli, A. Piccinno, D. Santoro, D. Del Buono, CP. Speer

. 2022 ; 35 (24) : 4739-4742. [pub] 20201220

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024166

OBJECTIVE: To assess at 24 months corrected age (CA) the neurological, respiratory, and general health status of children born prematurely from 27+0 to 33+6 weeks' gestation who were treated in a first-in-human study with a new fully synthetic surfactant (CHF5633) enriched with SP-B and SP-C proteins. OUTCOME MEASURES: Children were assessed using Bayley Scales of Infant Development (BSID), with a score below normal defined as BSID-II Mental Development Index score <70, or BSID-III cognitive composite score <85. In addition, a health status questionnaire was used to check for functional disability including respiratory problems and related treatments, sensory and neurodevelopment assessments, communication skills as well as the number of hospitalizations. RESULTS: 35 of 39 survivors had a neurodevelopmental assessment, 24 infants being evaluated by Bayley's Scales and 11 by health status questionnaires only. 23 children had scores within normal limits and one had BSID-III <85. The remaining 11 were judged clinically to have normal development. Health status questionnaires detected only issues that would normally be expected in preterm-born children. CONCLUSIONS: This assessment offers reassurance that treatment with CHF5633 surfactant was not associated with adverse neurodevelopmental, respiratory, or health outcomes by two years corrected age.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024166
003      
CZ-PrNML
005      
20250924080028.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14767058.2020.1863363 $2 doi
035    __
$a (PubMed)33345663
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sweet, David G $u Neonatal Unit, Royal Maternity Hospital, Belfast, Northern Ireland
245    12
$a A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes / $c DG. Sweet, M. Turner, Z. Straňák, R. Plavka, P. Clarke, B. Stenson, D. Singer, R. Goelz, L. Fabbri, G. Varoli, A. Piccinno, D. Santoro, D. Del Buono, CP. Speer
520    9_
$a OBJECTIVE: To assess at 24 months corrected age (CA) the neurological, respiratory, and general health status of children born prematurely from 27+0 to 33+6 weeks' gestation who were treated in a first-in-human study with a new fully synthetic surfactant (CHF5633) enriched with SP-B and SP-C proteins. OUTCOME MEASURES: Children were assessed using Bayley Scales of Infant Development (BSID), with a score below normal defined as BSID-II Mental Development Index score <70, or BSID-III cognitive composite score <85. In addition, a health status questionnaire was used to check for functional disability including respiratory problems and related treatments, sensory and neurodevelopment assessments, communication skills as well as the number of hospitalizations. RESULTS: 35 of 39 survivors had a neurodevelopmental assessment, 24 infants being evaluated by Bayley's Scales and 11 by health status questionnaires only. 23 children had scores within normal limits and one had BSID-III <85. The remaining 11 were judged clinically to have normal development. Health status questionnaires detected only issues that would normally be expected in preterm-born children. CONCLUSIONS: This assessment offers reassurance that treatment with CHF5633 surfactant was not associated with adverse neurodevelopmental, respiratory, or health outcomes by two years corrected age.
650    _2
$a vývoj dítěte $7 D002657
650    _2
$a předškolní dítě $7 D002675
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    12
$a nemoci nedonošenců $x farmakoterapie $7 D007235
650    _2
$a peptidové fragmenty $7 D010446
650    _2
$a fosfatidylcholiny $x terapeutické užití $7 D010713
650    _2
$a protein B asociovaný s plicním surfaktantem $7 D037701
650    _2
$a protein C asociovaný s plicním surfaktantem $7 D037721
650    12
$a syndrom respirační tísně novorozenců $x farmakoterapie $7 D012127
655    _2
$a časopisecké články $7 D016428
700    1_
$a Turner, Mark $u Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
700    1_
$a Straňák, Zbynek $u Department of Neonatology, Institute for the Care of Mother and Child, Prague, Czech Republic $1 https://orcid.org/0000000170953198
700    1_
$a Plavka, Richard $u Division of Neonatology, Department of Obstetrics and Gynecology, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Clarke, Paul $u Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK $1 https://orcid.org/0000000162037632
700    1_
$a Stenson, Ben $u Neonatal Unit, Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, UK
700    1_
$a Singer, Dominique $u Sektion Neonatologie und Pädiatrische Intensivmedizin, Zentrum für Geburtshilfe, Kinder- und Jugendmedizin, Universitätsklinikum Eppendorf, Hamburg, Germany
700    1_
$a Goelz, Rangmar $u Department of Neonatology, University Children's Hospital Tuebingen, Tuebingen, Germany
700    1_
$a Fabbri, Laura $u Global Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy
700    1_
$a Varoli, Guido $u Global Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy
700    1_
$a Piccinno, Annalisa $u Global Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy
700    1_
$a Santoro, Debora $u Global Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy
700    1_
$a Del Buono, Dorothea $u Global Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy
700    1_
$a Speer, Christian, $d 1952- $u University Children's Hospital, University of Würzburg, Würzburg, Germany $7 xx0335258
773    0_
$w MED00007048 $t Journal of maternal-fetal & neonatal medicine $x 1476-7058 $g Roč. 35, č. 24 (2022), s. 4739-4742
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33345663 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20250924080024 $b ABA008
999    __
$a ok $b bmc $g 1854096 $s 1175456
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 35 $c 24 $d 4739-4742 $e 20201220 $i 1476-7058 $m Journal of maternal-fetal & neonatal medicine $n J Matern Fetal Neonatal Med $x MED00007048
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace